首页|Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico study
Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico study
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
Currently， a plethora of information has been accumulated concerning COVID-19， including the transmission pathway of SARs-CoV-2。 Thus， we retrieved targets associated with the development of COVID-19 via PubChem。 A total of 517 targets were identified， and signaling pathways responded after infection of SARs-CoV-2 in humans constructed a bubble chart using RPackage。 The bubble chart result suggested that the key signaling pathway against COVID-19 was the estrogen signaling pathway associated with AKT1， HSP90AB1， BCL2 targets。 The three targets have the strongest affinity with three ligands-Akti-1/2， HSP990， S55746， respectively。 In conclusion， this work provides three key elements to alleviate COVID-19 symptoms might be anti-inflammatory effects on SARsCoV-2-infected lung cells。
NSTL
Elsevier
